DNA methylation profiles in African American prostate cancer patients in relation to disease progression

Rohina Rubicz, Shanshan Zhao, Milan Geybels, Jonathan L. Wright, Suzanne Kolb, Brandy Klotzle, Marina Bibikova, Dean Troyer, Raymond Lance, Elaine A. Ostrander, Ziding Feng, Jian Bing Fan, Janet L. Stanford

Resultado de la investigación: Articlerevisión exhaustiva

19 Citas (Scopus)


This study examined whether differential DNA methylation is associated with clinical features of more aggressive disease at diagnosis and prostate cancer recurrence in African American men, who are more likely to die from prostate cancer than other populations. Tumor tissues from 76 African Americans diagnosed with prostate cancer who had radical prostatectomy as their primary treatment were profiled for epigenome-wide DNA methylation levels. Long-term follow-up identified 19 patients with prostate cancer recurrence. Twenty-three CpGs were differentially methylated (FDR q ≤ 0.25, mean methylation difference ≥ 0.10) in patients with vs. without recurrence, including CpGs in GCK, CDKL2, PRDM13, and ZFR2. Methylation differences were also observed between men with metastatic-lethal prostate cancer vs. no recurrence (five CpGs), regional vs. local pathological stage (two CpGs), and higher vs. lower tumor aggressiveness (one CpG). These results indicate that differentially methylated CpG sites identified in tumor tissues of African American men may contribute to prostate cancer aggressiveness.

Idioma originalEnglish (US)
Páginas (desde-hasta)10-16
Número de páginas7
EstadoPublished - ene. 2019
Publicado de forma externa

ASJC Scopus subject areas

  • Genetics


Profundice en los temas de investigación de 'DNA methylation profiles in African American prostate cancer patients in relation to disease progression'. En conjunto forman una huella única.

Citar esto